Coherus Plans About 30% Job Cut To Lower Its Path To Self-Funding

LOQTORZI sales rose 25%, but the cancer-drug company is narrowing development and targeting lower quarterly cash spending.

Share
Coherus Plans About 30% Job Cut To Lower Its Path To Self-Funding

Coherus Oncology, which sells the cancer treatment LOQTORZI, plans to cut about 30% of its workforce and concentrate tagmokitug development on esophageal cancer, according to results furnished with an SEC filing Monday. The company aims to lower the LOQTORZI sales needed to fund core cash spending, even as the drug's quarterly sales grew 25%.

A Lower Self-Funding Threshold

Chief Financial Officer Bryan McMichael expects the reductions to save $6 million–$7 million in quarterly core cash spending, with benefits arriving over the next two quarters. Management's sales threshold for covering that spending is now $25 million–$30 million per quarter, down from $30 million–$35 million.

LOQTORZI brought in $14.0 million in the third quarter, compared with $11.2 million a year earlier and $13.6 million in the second quarter—a 3% increase from the preceding quarter. Coherus attributed growing demand to more patients receiving treatment and longer treatment duration.

LOQTORZI helps the immune system attack tumors by blocking the PD-1 protein. It is the only FDA-approved treatment available in the U.S. for recurrent, locally advanced or metastatic nasopharyngeal carcinoma, a cancer of the upper throat. Coherus is seeking greater market share against chemotherapy alone and off-label immunotherapy.

Denny Lanfear, Coherus Oncology's chief executive officer, said: “We believe this approach can provide a path to financial self-sufficiency.”

Smaller Losses, Less Cash

Coherus narrowed its third-quarter loss from continuing operations to $38.9 million, or $0.25 per share, from $44.5 million, or $0.38 per share, a year earlier. Total revenue from continuing operations reached $14.3 million, versus $11.6 million, primarily because of higher LOQTORZI volumes.

Research spending fell to $22.6 million from $27.3 million, helped by fewer employees and lower infrastructure, clinical-trial and research-manufacturing costs. Selling and administrative expenses declined to $21.2 million from $24.9 million, primarily because of lower staffing and operating costs following the company's 2025 biosimilar exit.

Cash and marketable securities totaled $83.6 million at September 30, compared with $172.1 million at the end of 2025. Those balances included collections earmarked for transition-service obligations of $19.6 million and $65.1 million, respectively.

The transition also involved an August special dividend granting shareholders rights to net proceeds from remaining legacy biosimilar assets. An August 12 agreement with Innovatus Life Sciences Lending Fund I and other lenders provided a $55 million loan maturing in August 2031.

Esophageal Cancer Takes Priority

The narrower strategy follows interim findings reported October 29 showing antitumor activity in esophageal cancer and a safety profile Coherus considered manageable. Tagmokitug is designed to remove regulatory immune cells around tumors that can impede an immune attack; it is being tested with toripalimab, LOQTORZI's active ingredient.

Coherus will continue esophageal-cancer cohorts while deprioritizing other tagmokitug/toripalimab indications. It intends to seek FDA agreement on a new study in previously treated esophageal-cancer patients, including a proposed 700 mg dose, with the aim of accelerating development.

The company also plans to proceed with an early-stage study pairing tagmokitug with pasritamig in metastatic prostate cancer resistant to hormone-lowering treatment, expected to begin in fall 2026. Enrollment is complete in its mid-stage liver-cancer trial testing casdozokitug with toripalimab and bevacizumab.

Coherus expects the first results from the liver-cancer trial in the first half of 2027.

Sources

More on Coherus Oncology

All Coherus Oncology (CHRS) coverage →